Tuesday Features

Zalicus awaiting data on potential new pain medication

Zalicus (NASADQ:ZLCS) will have data in the second half of this year that will provide important insights into the potential of its lead drug candidate, Z160, to be a breakthrough new class of non-opioid analgesic for the treatment of both chronic and acute neuropathic pain. Justin Renz “There hasn’t been a lot of innovation in the pain space in... [Read more of this feature]

---

Galena to target Abstral as market leader for cancer pain

Galena Biopharma (NASDAQ:GALE) plans to make its recently acquired Abstral sublingual tablets the market leader for the treatment of breakthrough cancer pain (BTcP) in the U.S., matching the product’s performance in Europe. Mark J. Ahn, PhD “Abstral is the latest and best-in-class drug for this indication,” president and CEO Mark Ahn says in an... [Read more of this feature]

---

Oramed readies oral insulin study in U.S.

Oramed Pharmaceuticals (NASDAQ:ORMP) is awaiting a decision from the FDA, possibly later this week, to conduct a sub-study of the safety of its oral insulin candidate, ORMD-0801, before proceeding to a large, multi-center Phase 2 clinical trial later this year. Nadav Kidron “Approving a clinical trial in the U.S. for oral insulin is a big deal,”... [Read more of this feature]

---

More Posts From Tuesday Features

Briefs

Canaccord ups TearLab price target to $14

Canaccord Genuity has raised its price target on “buy-rated” TearLab (NASDAQ:TEAR; TSX:TLB) to $14 from $10, saying it recently conducted interviews of TearLab users and found high levels of satisfaction from its customers. The stock closed at $9.55 on Wednesday. “As a result, we gained comfort with our near-term assumptions and increased our... [Read more of this brief]

---

Soricimed adds first U.S. site to cancer trial

Closely-held Soricimed Biopharma has added a third site and first U.S. site to its Phase 1 clinical trial, with the first patient beginning treatment this week with its anti-cancer agent SOR-C13 at The University of Texas MD Anderson Cancer Center in Houston. The trial is a multicenter, open-label, dose escalation study that is taking place at cancer... [Read more of this brief]

---

Ohr Pharma names June Almenoff to board

Dr. June Almenoff Ohr Pharmaceutical (OTCQB: OHRP)has appointed Dr. June Almenoff to the board of directors. In a statement, CEO Dr. Irach Taraporewala said Dr. Almenoff offers tremendous expertise in the areas of pharmaceutical research and development, risk management, and product licensing. “We look forward to working with June as we continue... [Read more of this brief]

---

Aradigm inks development pact with Grifols

Grifols (NASDAQ:GRFS) of Spain and Aradigm (OTCBB:ARDM) have signed an exclusive, worldwide license for Aradigm’s proprietary formulations of inhaled ciprofloxacin (Pulmaquin and Lipoquin) for the treatment of severe respiratory diseases, including non-cystic fibrosis bronchiectasis (BE). Aradigm has completed Phase 2b clinical trials in BE patients... [Read more of this brief]

---

Oramed cleared for oral insulin trials in U.S.

The FDA has cleared Oramed Pharmaceuticals’ (NASDAQ:ORMP) Investigational New Drug application for ORMD-0801, its oral insulin capsule. Nadav Kidron “We are very pleased to have the FDA clearance to proceed,” CEO Nadav Kidron said in a statement. “The upcoming trial is a major milestone for Oramed and we look forward to continuing... [Read more of this brief]

---

More Posts From Briefs